ArticleCancer biology & medicine2017
Overdiagnosis of breast cancer in population screening: does it make breast screening worthless?
Article in Cancer biology & medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Supplemental Screening as an Adjunct to Mammography for Breast Cancer Screening in People With Dense Breasts: A Health Technology Assessment.Ontario health technology assessment series · 2023Pooled it
- Impact of Full-Field Digital Mammography Versus Film-Screen Mammography in Population Screening: A Meta-Analysis.Journal of the National Cancer Institute · 2021Pooled it
- Cost-effectiveness of mammography-based breast cancer screening in Jordan: a healthcare system perspective.Breast cancer (Tokyo, Japan) · 2026Article
- Metabolic Fingerprinting of Urine Reveals Metabolite Changes in Women With Breast Cancer.Cancer medicine · 2026Article
- Steroidogenic Acute Regulatory Protein in Breast Cancer: Mechanistic Insights into Pathogenesis and Therapeutics.International journal of molecular sciences · 2026Review
- Social Drivers of Guideline-Discordant Breast Cancer Screening by Age and Mortality Risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Analysing Breast Cancer Screening Trends in Rural Saudi Arabia: Vision 2030 Context.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- The Urinary Proteome Differs with the Presence and Type of Breast Cancer.Journal of proteome research · 2025Article
- Artificial Intelligence-Driven Personalization in Breast Cancer Screening: From Population Models to Individualized Protocols.Cancers · 2025Review
- Association Between Microcalcification Patterns in Mammography and Breast Tumors in Comparison to Histopathological Examinations.Diagnostics (Basel, Switzerland) · 2025Article
- Impact of Method of Detection of Breast Cancer on Clinical Outcomes in Individuals Aged 40 Years or Older.Radiology. Imaging cancer · 2025Observational
- Detecting Collagen by Machine Learning Improved Photoacoustic Spectral Analysis for Breast Cancer Diagnostics: Feasibility Studies With Murine Models.Journal of biophotonics · 2025Article
- Understanding the mechanisms underlying the socioeconomic disparities in cancer screening among Australian women.BMC public health · 2024Article
- Implementation considerations for risk-tailored cancer screening in the population: A scoping review.Preventive medicine · 2024Article
- Communicating the results of risk-based breast cancer screening through visualizations of risk: a participatory design approach.BMC medical informatics and decision making · 2024Article
- Article
- Epidemiology of Breast Cancer Mortality in Kazakhstan, trends and Geographic Distribution.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- The contribution of prognostic factors to socio-demographic inequalities in breast cancer survival in Victoria, Australia.Cancer medicine · 2023Article
- The Promise of Artificial Intelligence in Digestive Healthcare and the Bioethics Challenges It Presents.Medicina (Kaunas, Lithuania) · 2023Review
- Acceptability of Automated Robotic Clinical Breast Examination: Survey Study.Journal of participatory medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The risk of breast cancer (BC) overdiagnosis attributed to mammography screening is an unresolved issue, complicated by heterogeneity in the methodology of quantifying its magnitude, and both political and scientific elements surrounding interpretation of the evidence on this phenomenon. Evidence from randomized trials and also from observational studies shows that mammography screening reduces the risk of BC death; similarly, these studies provide sufficient evidence that overdiagnosis represents a serious harm from population breast screening. For both these outcomes of screening, BC mortality reduction and overdiagnosis, estimates of magnitude vary between studies however overdiagnosis estimates are associated with substantial uncertainty. The trade-off between the benefit and the collective harms of BC screening, including false-positives and overdiagnosis, is more finely balanced than initially recognized, however the snapshot of evidence presented on overdiagnosis does not mean that breast screening is worthless. Future efforts should be directed towards (a) ensuring that any changes in the implementation of BC screening optimize the balance between benefit and harms, including assessing how planned or actual changes modify the risk of overdiagnosis; (b) informing women of all the outcomes that may affect them when they participate in screening using well-crafted and balanced information; and
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.